Exploring function of long non-coding RNA TUG1 in hepatocellar carcinoma via transcriptomic analysis
Abstract
Hepatocellular carcinoma (HCC) is the most predominant form of primary liver cancer and remains among the top three cancer-related deaths, with incidence and mortality rate projected to rise through 2040. Long non-coding RNAs (lncRNAs) have been implicated in tumorigenesis of various cancers, including HCC. Taurine upregulated gene (TUG1), one of the earliest identified pro-tumorigenic lncRNAs in HCC, is highly expressed in HCC patients. However, TUG1 impact on HCC cells’ transcriptomes remains largely unexplored. In the present study, RNA-sequencing was performed on TUG1-depleted HepG2 cell to obtain transcriptomic data. Through a series of transcriptomic analysis, glycolysis was ranked as the top-hit pathway followed by depletion of TUG1. This was further supported by positive correlation between TUG1 and glycolysis genes in clinical HCC patients’ data. To investigate the molecular function of TUG1, computational predictions were employed to explore competitive endogenous (ceRNA) models and reveal the putative miRNA response elements (MREs) on candidate miRNAs. MiR-122-5p was identified as potential tumor-suppressing RNA targeted for TUG1/glycolysis axis which exhibited the strongest negative correlation with TUG1-related genes, ALDOA and PKM. Dual-luciferase assay confirmed the interaction between TUG1 and miR-122-5p. In addition, miR-122-5p-meidated negative regulation on ALDOA and PKM was confirmed by the same assay. Moreover, induction of antagomiR against miR-122-5p partially increased glucose uptake, ATP production, and lactate production following knockdown of TUG1. Collectively, these results suggest that TUG1 promotes glycolysis in HCC by sponging miR-122-5p to upregulate ALDOA and PKM, highlighting TUG1 as a potential therapeutic target for antiglycolytic strategies in HCC.